ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 114.7% in December

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 300,239 shares, a growth of 114.7% from the November 30th total of 139,873 shares. Based on an average daily volume of 5,452,214 shares, the short-interest ratio is presently 0.1 days. Currently, 7.2% of the company’s stock are short sold. Currently, 7.2% of the company’s stock are short sold. Based on an average daily volume of 5,452,214 shares, the short-interest ratio is presently 0.1 days.

ProPhase Labs Trading Down 15.4%

Shares of PRPH stock traded down $0.10 during mid-day trading on Friday, reaching $0.52. 1,250,862 shares of the stock traded hands, compared to its average volume of 2,615,972. The company has a market cap of $2.40 million, a price-to-earnings ratio of -1.33 and a beta of -0.66. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of 0.14. The stock’s fifty day simple moving average is $0.28 and its two-hundred day simple moving average is $0.36. ProPhase Labs has a 1-year low of $0.50 and a 1-year high of $9.35.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.88 million during the quarter, compared to the consensus estimate of $5.69 million. ProPhase Labs had a negative return on equity of 482.05% and a negative net margin of 825.01%. On average, research analysts anticipate that ProPhase Labs will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on PRPH. Weiss Ratings reiterated a “sell (e+)” rating on shares of ProPhase Labs in a report on Wednesday, October 8th. Wall Street Zen raised shares of ProPhase Labs to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of ProPhase Labs

Several hedge funds and other institutional investors have recently modified their holdings of PRPH. Sykon Capital LLC bought a new position in shares of ProPhase Labs in the 2nd quarter worth approximately $252,000. Susquehanna International Group LLP increased its stake in ProPhase Labs by 290.1% during the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares in the last quarter. Josh Arnold Investment Consultant LLC purchased a new position in ProPhase Labs in the 1st quarter worth approximately $100,000. Accretive Wealth Partners LLC purchased a new stake in shares of ProPhase Labs during the third quarter valued at $114,000. Finally, Apollon Wealth Management LLC bought a new position in ProPhase Labs during the third quarter valued at approximately $84,000. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.